|
Título:
|
Reducing the global burden of HTLV-1 infection: An agenda for research and action
|
|
Autores:
|
Willems, Luc ;
Hasegawa, Hideki ;
Accolla, Roberto ;
Bangham, Charles ;
Bazarbachi, Ali ;
Bertazzoni, Umberto ;
Carneiro-Proietti, Anna Barbara de Freitas ;
Cheng, Hua ;
Chieco-Bianchi, Luigi ;
Ciminale, Vincenzo ;
Coelho-dos-Reis, Jordana ;
Esparza, José ;
Gallo, Robert C. ;
Gessain, Antoine ;
Gotuzzo, Eduardo ;
Hall, William ;
Harford, Joseph ;
Hermine, Olivier ;
Jacobson, Steven ;
Macchi, Beatrice ;
Macpherson, Calum ;
Mahieux, Renaud ;
Matsuoka, Masao ;
Murphy, Edward ;
Peloponese, Jean-Marie ;
Simon, Viviana ;
Tagaya, Yutaka ;
Taylor, Graham P. ;
Watanabe, Toshiki ;
Yamano, Yoshihisa
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Elsevier Masson, 2019-04-25T15:46:34Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
Even though an estimated 10–20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines. © 2016 Elsevier B.V.
|
|
En línea:
|
http://doi.org/10.1016/j.antiviral.2016.10.015
|
